{"id":"W4392376557","doi":"10.1158/1538-7445.ovarian23-a074","title":"Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Cyclophosphamide; Oncology; Internal medicine; Ovarian cancer; Cancer; Gynecology; Chemotherapy; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001112005,0.0006560076,0.0008800992,0.0002263832,0.0001847485,0.0007068494,0.0004954342,0.000782199,0.005624457],"category_scores_gemma":[0.0007157469,0.000177471,0.001010705,0.000200281,0.0003889904,0.0006055835,0.0002282861,0.001579974,0.0007603394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000530389,"about_ca_system_score_gemma":0.0008264537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005777588,"about_ca_topic_score_gemma":0.001270642,"domain_scores_codex":[0.9996,0.0002512018,0.00002339678,0.00004278292,0.00003406817,0.00004861209],"domain_scores_gemma":[0.9994748,0.0001263645,0.0001178785,0.00003625212,0.00004638141,0.0001983513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8457878,0.01046939,0.004864539,0.001066952,0.001959132,0.000149338,0.00007342202,0.001109194,0.02943175,0.0002846955,0.009174646,0.09562916],"study_design_scores_gemma":[0.6831468,0.2820469,0.0193832,0.0001682021,0.001405112,0.0002773187,0.00004612925,0.001031764,0.005815511,0.0002862224,0.006370309,0.0000225473],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.9870707,0.004912124,0.0003467532,0.001077065,0.0001928216,0.0009552921,0.001885912,0.0001220512,0.003437179],"genre_scores_gemma":[0.9858788,0.002491648,0.0008591317,0.001193787,0.0003276411,0.0008798162,0.00394653,0.00004040342,0.00438228],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.005624457,"threshold_uncertainty_score":0.01881564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08518002733598602,"score_gpt":0.4227666161066388,"score_spread":0.3375865887706528,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}